• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply: Aspirin and GLP-1RAs-The missing confounders of empagliflozin for MASLD without diabetes mellitus?

作者信息

Cheung Ka Shing, Leung Wai K

机构信息

Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.

出版信息

Hepatology. 2025 Jan 1;81(1):E23. doi: 10.1097/HEP.0000000000001034. Epub 2024 Jul 24.

DOI:10.1097/HEP.0000000000001034
PMID:39047080
Abstract
摘要

相似文献

1
Reply: Aspirin and GLP-1RAs-The missing confounders of empagliflozin for MASLD without diabetes mellitus?回复：阿司匹林与胰高血糖素样肽-1受体激动剂——恩格列净治疗非糖尿病性代谢相关脂肪性肝病时被遗漏的混杂因素？
Hepatology. 2025 Jan 1;81(1):E23. doi: 10.1097/HEP.0000000000001034. Epub 2024 Jul 24.
2
Letter to the Editor: Aspirin and GLP-1RAs-The missing confounders of empagliflozin for MASLD without diabetes mellitus?
Hepatology. 2025 Jan 1;81(1):E21-E22. doi: 10.1097/HEP.0000000000001033. Epub 2024 Jul 24.
3
Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes.胰高血糖素样肽-1 受体激动剂对代谢功能障碍相关脂肪性肝病肝硬化和 2 型糖尿病患者不良肝脏结局风险的影响。
Aliment Pharmacol Ther. 2024 May;59(9):1096-1110. doi: 10.1111/apt.17925. Epub 2024 Mar 27.
4
Integrated Management of Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs.心血管-肾脏-肝脏-代谢综合征的综合管理：钠-葡萄糖协同转运蛋白2抑制剂、胰高血糖素样肽-1受体激动剂及胃抑肽/胰高血糖素样肽-1受体激动剂的作用拓展
Biomedicines. 2025 Jan 8;13(1):135. doi: 10.3390/biomedicines13010135.
5
Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.胰高血糖素样肽-1受体激动剂治疗代谢功能障碍相关脂肪性肝病患者的疗效与安全性：一项随机对照试验的系统评价和荟萃分析
Cureus. 2024 Oct 13;16(10):e71366. doi: 10.7759/cureus.71366. eCollection 2024 Oct.
6
Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot.胰高血糖素样肽-1受体激动剂作为代谢功能障碍相关脂肪性肝病和肥胖症的一种有前景的治疗选择：一箭双雕。
Curr Opin Gastroenterol. 2025 May 1;41(3):104-109. doi: 10.1097/MOG.0000000000001083. Epub 2025 Feb 13.
7
Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark.在丹麦常规临床护理中恩格列净与胰高血糖素样肽-1受体激动剂的医疗资源利用及成本比较
Diabetes Ther. 2022 Dec;13(11-12):1891-1906. doi: 10.1007/s13300-022-01323-y. Epub 2022 Oct 31.
8
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists.胰高血糖素样肽-1受体激动剂在代谢功能障碍相关脂肪性肝炎患者中的多效性作用：胃肠病学家的综述
Expert Opin Investig Drugs. 2025 Mar;34(3):169-195. doi: 10.1080/13543784.2025.2473062. Epub 2025 Mar 17.
9
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?胰高血糖素样肽-1（GLP-1）受体激动剂，我们是否正在见证神经-心脏-代谢紊乱治疗范式转变的出现？
Pharmacol Ther. 2025 May;269:108824. doi: 10.1016/j.pharmthera.2025.108824. Epub 2025 Feb 19.
10
National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.2015 年至 2020 年，心脏病专家和其他专业医生使用钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的全国趋势。
J Am Heart Assoc. 2022 May 3;11(9):e023811. doi: 10.1161/JAHA.121.023811. Epub 2022 Apr 27.

引用本文的文献

1
Empagliflozin for non-diabetic metabolic dysfunction-associated steatotic liver disease: a promising therapeutic agent in transition.恩格列净用于非糖尿病性代谢功能障碍相关脂肪性肝病：一种正处于转变中的有前景的治疗药物。
Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):651-654. doi: 10.21037/hbsn-2025-250. Epub 2025 Jul 25.